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The angiotensin type 2 (AT2) receptor of angiotensin II has long been thought to be limited to
few tissues, with the primary effect of counteracting the angiotensin type 1 (AT1)receptor.
Functional studies in neuronal cells have demonstrated AT2 receptor capability to modu-
late neuronal excitability, neurite elongation, and neuronal migration, suggesting that it may
be an important regulator of brain functions. The observation that the AT2 receptor was
expressed in brain areas implicated in learning and memory led to the hypothesis that it
may also be implicated in cognitive functions. However, linking signaling pathways to phys-
iological effects has always proven challenging since information relative to its physiological
functions has mainly emerged from indirect observations, either from the blockade of the
AT1receptor or through the use of transgenic animals. From a mechanistic standpoint,
the main intracellular pathways linked to AT2 receptor stimulation include modulation of
phosphorylation by activation of kinases and phosphatases or the production of nitric oxide
and cGMP, some of which are associated with the Gi-coupling protein. The receptor can
also interact with other receptors, either G protein-coupled such as bradykinin, or growth
factor receptors such as nerve growth factor or platelet-derived growth factor receptors.
More recently, new advances have also led to identiﬁcation of various partner proteins,
thus providing new insights into this receptor’s mechanism of action. This review summa-
rizes the recent advances regarding the signaling pathways induced by the AT2 receptor
in neuronal cells, and discussed the potential therapeutic relevance of central actions of
this enigmatic receptor. In particular, we highlight the possibility that selective AT2 recep-
tor activation by non-peptide and selective agonists could represent new pharmacological
tools that may help to improve impaired cognitive performance in Alzheimer’s disease and
other neurological cognitive disorders.
Keywords: AT2 receptor, angiotensin, brain, differentiation, regeneration, neurodegenerative disorders, signaling,
cognitive functions
INTRODUCTION
It is now well accepted that the effects of the various compo-
nents of the renin-angiotensin system (RAS) range in various
aspects of peripheral and brain functions well beyond those of
regulating blood pressure and hydro-mineral balance. In par-
ticular, the existence of a complete RAS in the brain is fully
acknowledged. Its activation leads to angiotensin II (Ang II)
production, which is usually viewed as the end-product of this
system (de Gasparo et al., 2000). Ang II binds two receptors
from the G protein-coupled receptor family (GPCR), namely the
angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptor.
Although physiological functions of the AT1receptor are relatively
well-established, ranging from vasoconstriction and aldosterone
release to cell growth, the effects associated with the AT2 recep-
tor are surrounded by controversy. Both AT1 and AT2 receptors
are expressed in various brain areas involved in the regulation of
ﬂuid and electrolyte balance and in the regulation of arterial pres-
sure, as well as in structures involved in cognition, behavior, and
locomotion (Phillips and de Oliveira, 2008; Horiuchi et al., 2010;
Horiuchi and Mogi, 2011; Wright and Harding, 2011, 2012; Mogi
and Horiuchi, 2012).
One of the biggest challenges in studying the AT2 receptor is to
apply what has been observed using cell lines to in vivo models.
Indeed, studies using cell lines expressing the AT2 receptor either
endogenously or by transfection, have provided paramount infor-
mation regarding its intracellular mechanisms of action, although
associating thesemechanismswith biological functions has proven
to be much more difﬁcult. Indeed, most of the relevant informa-
tion regarding AT2 receptor functions in the brain has emerged
from indirect observations, either by use of AT1 receptor blockers
(ARB) or via transgenic “knock-down” animals for AT2 receptor
expression. The present review summarizes recent advances in
AT2 receptor signaling pathways, and discusses how they could be
related to the neuroprotective functions of the receptor.
BRAIN EXPRESSION AND ROLE OF THE AT2 RECEPTOR
As summarized in several reviews (de Gasparo et al., 2000; Por-
rello et al., 2009; Gallo-Payet et al., 2011; Wright and Harding,
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2011; Mogi and Horiuchi, 2012), the AT2 receptor is widely
expressed during fetal life, which decreases rapidly after birth
(Grady et al., 1991; Breault et al., 1996; Schutz et al., 1996; Nuyt
et al., 1999), although a recent study has reported opposite results
(Yu et al., 2010). This study is indeed in sharp contrast with previ-
ous reports using more speciﬁc methods, like autoradiography or
in situ hybridization. In the adult, AT2 receptor expression is lim-
ited to a few tissues and cell types, such as vascular endothelial cells,
adrenal gland, kidney, heart, myometrial cells, and ovaries (review
in Porrello et al., 2009; Gallo-Payet et al., 2011, 2012;Verdonk et al.,
2012). In the adult central nervous system (CNS), theAT2 receptor
is observed in certain speciﬁc brain areas involved in the control
and learning of motor activity, control of autonomous functions,
sensory areas, and selected limbic system structures (Lenkei et al.,
1996, 1997). In particular, it is the major Ang II receptor in the
medulla oblongata (control of autonomous functions), septum
and amygdala (associated with anxiety-like behavior), thalamus
(sensory perception), superior colliculus (control of eye move-
ments in response to visual information) as well as subthalamic
nucleus and cerebellum (areas associated with learning of motor
functions). On the other hand, certain areas involved in cardiovas-
cular functions, learning, behavior, and stress reactions (cingulate
cortex,molecular layer of the cerebellar cortex, superior colliculus,
and paraventricular nuclei) contain both AT1 and AT2 receptors
(Millan et al., 1991; Tsutsumi and Saavedra, 1991; Lenkei et al.,
1996, 1997). More recently, expression of theAT2 receptor was also
detected in the substantia nigra pars compacta, an area involved
in dopaminergic signals and associated with Parkinson’s disease
(Grammatopoulos et al., 2007), and in the hippocampus (Arga-
naraz et al., 2008; AbdAlla et al., 2009). At the cellular level, the
AT2 receptor is expressed in neurons, but not in astrocytes (Bot-
tari et al., 1992a; Lenkei et al., 1996; Gendron et al., 2003). Evidence
also suggests that the AT2 receptor is expressed in the vasculature
wall, where it acts on cerebral blood ﬂow (review in Horiuchi
and Mogi, 2011; Horiuchi et al., 2012). It should also be noted that
existence of a non-AT1/non-AT2 receptor in theCNShas been sug-
gested, which displays high afﬁnity forAng I, II, and III (Karamyan
and Speth, 2007).
ROLE OF THE AT2 RECEPTOR IN NEURONAL EXCITABILITY
One of the ﬁrst roles of the AT2 receptor to be identiﬁed was
the modulation of neuronal excitability, which plays a crucial
role not only in neuronal differentiation, but also in neuronal
functions (review in Gendron et al., 2003; Gao et al., 2011). In par-
ticular, in cells of neuronal origin, activation of the AT2 receptor
decreases activity of T-type calcium channels (Buisson et al., 1992,
1995). On the other hand, in rat brain neuronal culture, Kang
et al. (1994) showed that the AT2 receptor stimulates a delayed
rectiﬁer K+ current (IK) and a transient K+ current (IA), an
effect dependent on the G-protein Gi and the serine/threonine
phosphatase PP2A. Consistent with these observations, a recent
study showed that AT2 receptor induces a hyperpolarization and a
decrease in ﬁring rate in rostral ventrolateral medulla (RVLM)
neurons suggesting that central activation of the AT2 receptor
in this region decreases excitability (Matsuura et al., 2005). More
recently, another study using C21/M024 demonstrated that selec-
tive stimulation of AT2 receptor in the neuronal cell line (called
CATH.a neurons) increases the potassium current activity (IKv) in
a nitric oxide (NO)-dependant pathway (Gao et al., 2011). More-
over, intracerebroventricular infusion of C21/M024was associated
with a decrease in norepinephrine excretion and in blood pressure.
Indeed, the modulation of the receptor on neuronal excitability in
this region could be one of the mechanism associated with its
effect on blood pressure, since RVLM is often considered as the
main regulator of vascular tone (review in Dupont and Brouw-
ers, 2010). An inhibitory effect of the AT2 receptor on neuronal
excitability has also been observed in the locus coeruleus from
brain slice preparations (Xiong and Marshall, 1994) and in the
superior colliculus (Merabet et al., 1997). Finally, using the selec-
tive agonist C21/M024, Jing et al. (2012) recently demonstrated
that direct stimulation of cerebral AT2 receptor increases postsy-
naptic potential, thus corroboratingprevious in vitroobservations.
Interestingly,AT2 receptor-induced neuronal activation of delayed
rectiﬁer potassium channels has also been demonstrated to have
a neuroprotective effect (Grammatopoulos et al., 2004a). In fact,
these AT2 receptor effects on ionic channel activity suggest that
it may be implicated in synaptic plasticity, an important process
involved in learning and memory.
ROLE OF THE AT2 RECEPTOR IN NEURONAL DIFFERENTIATION
One of the best recognized effects of AT2 receptor stimulation in
neuronal cells is the induction of neurite outgrowth (review in
Gallo-Payet et al., 2011). In the early 1990s, our group observed
that stimulation of the AT2 receptor with its selective agonist
CGP42112A induces neurite outgrowth in the neuronalNG108-15
cell line (Laﬂamme et al., 1996), results that were further con-
ﬁrmed using the recently developed non-peptide selective AT2
receptor agonist C21/M024 (Wan et al., 2004). This effect was
associated with an increase in mature neural cell markers, such as
βIII-tubulin, and microtubule-associated proteins (MAPs) such as
MAP2c (Laﬂamme et al., 1996), both known to stabilize tubulin
in a polymerized state, thus participating actively in differentia-
tion (Sanchez et al., 2000). Similar results have also been reported
in the pheochromocytoma-derived cell line PC12W, where Ang
II was found to promoted neuronal differentiation characterized
by an increase in neurite elongation (Meffert et al., 1996) and
enhanced levels of polymerized βIII-tubulin and MAP2 associ-
ated with microtubules (Stroth et al., 1998). However, neurite
outgrowth in PC12W cells has also been associated with a reduced
expression of MAP1B (Stroth et al., 1998) and neuroﬁlament M
(Gallinat et al., 1997), two proteins speciﬁcally associated with
axon elongation (Gordon-Weeks, 1991). These results were fur-
ther conﬁrmed in primary neuronal cultures, including retinal
explants (Lucius et al., 1998), microexplant cultures of the cere-
bellum (Coté et al., 1999), in neurospheres from mouse fetal brain
(Mogi et al., 2006) as well as primary cultures of newborn brain
cortex neurons (Li et al., 2007) and hippocampal neurons (Jing
et al., 2012). Some studies also showed that this neurite elongation
was associated with an increase in the repair of damaged DNA
by induction of methyl methanesulfonate sensitive-2 (MMS2), a
neural-differentiating factor (Mogi et al., 2006; Jing et al., 2012).
Altogether, these results suggest that activation of the AT2 receptor
is associated with important rearrangements of the cytoskeleton
necessary for induction of neurite elongation.
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ROLE OF THE AT2 RECEPTOR IN NEURONAL MIGRATION
In cerebellar microexplants, where both neuronal and glial cells
are present, AT2 receptor activation induces not only neurite out-
growth, but cell migration as well (Coté et al., 1999). Indeed,
application of Ang II in this model induced cell migration of
neurons from the center toward the periphery of the microex-
plant (Coté et al., 1999). These effects were more pronounced
in cells treated with Ang II and DUP 753 (known as the ARB
losartan) or in cells treated with 10 nM of CGP42112A an AT2
receptor agonist, and conversely blocked with the AT2 recep-
tor antagonist PD123,319. Similar cell migration has also been
observed during AT2 receptor-induced regeneration of post-natal
retinal microexplants (Lucius et al., 1998). During migration and
neurite outgrowth, cells are characterized by a myriad of advanc-
ing, retracting, turning, and branching behavioral patterns. Such
dynamics and plasticity are driven by the reorganization of actin
and the microtubular cytoskeleton. In particular, during the pro-
cess of migration, actin ﬁlaments play a major role and are
putatively considered as the primary target of guidance cues, due
to their localization at the cell periphery, and in ﬁlopodium in
the growth cone, where they are considered to be the driving
force for the forward extension of the cell membrane (Gallo and
Letourneau, 2004; Kalil and Dent, 2005). Our results on NG108-
15 cells have shown that the underlying mechanism involves an
Ang II-induced decrease in the amount of F-actin in ﬁlopodium
and an increase in the pool of unpolymerized actin, through a
pertussis toxin (PTX)-sensitive increase in ADF/coﬁlin activity.
These latter effects were found to be AT2 receptor-dependent,
since the increase in the rate of migration was abolished by
the selective antagonist PD123,319, but not by the selective AT1
receptor antagonist losartan. Interestingly, some co-localization of
F-actinwithmicrotubules was also observed in control conditions,
but which disappeared during Ang II-induced migration (Kilian
et al., 2008). Among the candidate molecules that possibly cross-
link actin ﬁlaments and microtubules are MAP2c and MAP1B
(Dehmelt et al., 2003; Dehmelt and Halpain, 2004), proteins pre-
viously shown by our group to be affected during the process
of AT2 receptor-stimulated neurite outgrowth, both in NG108-
15 cells and in cerebellar granule cells (Laﬂamme et al., 1996;
Coté et al., 1999).
MAIN SIGNALING PATHWAYS OF THE AT2 RECEPTOR
Although the AT2 receptor displays most of the classical fea-
tures of a GPCR, it is usually considered as an atypical member
of this family, since it fails to induce all of the classical signal-
ing pathways such as cAMP, production of inositol triphosphate
(IP3) or intracellular calcium release. Signaling pathways asso-
ciated with the AT2 receptor mainly involve a balance between
phosphatase and kinase activities and according to whether the
cell is undifferentiated or differentiated and whether it expresses
angiotensin AT1 receptors or not. Thus, there is still much contro-
versy surrounding this receptor, and its effects, either protective
or deleterious, remain a subject of debate (Widdop et al., 2003;
Steckelings et al., 2005, 2010; Porrello et al., 2009; Horiuchi et al.,
2012;Verdonk et al., 2012). In our endeavor to elucidate the mech-
anisms associated with AT2 receptor-induced neurite outgrowth,
we and others have investigated signaling pathways activated by
this receptor, including G-protein coupling, regulation of kinase
activity, interaction with growth factor receptors, and produc-
tion of NO. Moreover, recent observations have also delineated
new partners for the AT2 receptor which play key functions in its
regulation (Figure 1).
G-PROTEIN COUPLING
While coupling of G-protein to AT1 receptors is well described
(de Gasparo et al., 2000; Hunyady and Catt, 2006), such cou-
pling is not the rule for the AT2 receptor. Former studies have
described a coupling to subunit Gαi2 and Gαi3 in rat fetus (Zhang
and Pratt, 1996). In some models (rat hippocampal neurons and
other selected cell types), blocking Gαi with PTX or antibodies
directed against Gαi inhibited the AT2 receptor effects on actin
depolymerization, activation of endothelial NO synthase (NOS),
stimulationof neuronalK+ current andonanti-proliferative activ-
ity (Kang et al., 1994; Ozawa et al., 1996; Li et al., 2004; Olson
et al., 2004; Kilian et al., 2008), indicating that coupling of the
AT2receptor to Gαi is at least implicated in these pathways. How-
ever, aside from a few exceptions (Kang et al., 1994), PTX failed
to inhibit either p42/p44mapk activation in the neuronal cell line
NG108-15 (Gendron et al., 2002) or phosphatase activity in sev-
eral models (for review see Nouet and Nahmias, 2000; Gendron
et al., 2003).
REGULATION OF KINASE ACTIVITY
AT2 Receptor-induced phosphatase activation
Phosphatase activation has been one of the ﬁrst signals associ-
ated with AT2 receptor activation. After the earlier studies in
PC12W cells (Bottari et al., 1992b; Brechler et al., 1994), results
have been conﬁrmed in other cell lines, including N1E-115 cells
(Nahmias et al., 1995), NG108-15 cells (Buisson et al., 1995), and
R3T3 ﬁbroblasts (Tsuzuki et al., 1996a,b). This phosphatase acti-
vation by the AT2 receptor is essential for its anti-proliferative
and pro-apoptotic effects (for reviews, see Nouet and Nahmias,
2000; Steckelings et al., 2005; Porrello et al., 2009; Verdonk et al.,
2012). Currently, three main phosphatases have been impli-
cated in AT2 receptor signaling, namely SH2-domain-containing
phosphatase 1 (SHP-1), mitogen-activated protein kinase phos-
phatase 1 (MKP-1), and the serine–threonine phosphatase
PP2A.
SHP-1 is a cytosolic phosphatase rapidly activated by the
AT2 receptor following Ang II binding. Activation of SHP-1 is
associated with AT2-induced growth inhibition in various cells,
including neuronal cells (Bedecs et al., 1997; Elbaz et al., 2000;
Feng et al., 2002; Li et al., 2007), vascular smooth muscle cells (Cui
et al., 2001; Matsubara et al., 2001), CHO, and COS-7 cells trans-
fected with the AT2 receptor (Elbaz et al., 2000; Feng et al., 2002).
Activation of SHP-1 is associated with inhibitory effects of the
AT2 receptor on the AT1 receptor, including transactivation of the
epidermal growth factor (EGF) receptor and activation of c-Jun
N-terminal kinase (JNK) (Matsubara et al., 2001; Shibasaki et al.,
2001), but also on insulin-induced activation of the phosphatidyli-
nositol 3-kinase (PI3K), its association with the insulin receptor
substrate IRS-2 and phosphorylation of Akt (Cui et al., 2001). This
inhibition of insulin signaling by AT2 receptor-induced SHP-1
activation has also been associated with an increase in PC12W
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FIGURE 1 | Main signaling pathways associated with AT2 receptor activation leading to neuroprotective effects (see text for details). Adapted from
Gallo-Payet et al. (2011).
cell apoptosis (Cui et al., 2002). More recently, Li et al. (2007)
have shown that induction of neurite outgrowth in fetal rat neu-
rons by AT2 receptor involves the association of SHP-1 with
the newly identiﬁed AT2-receptor interacting protein (ATIP; see
section AT2 Receptor Interacting Proteins) and an increase in
MMS2 protein (Li et al., 2007). Finally, although the mechanisms
associated withAT2 receptor-induced activation of SHP-1 have yet
to be fully elucidated, implication of G-protein coupling (Bedecs
et al., 1997; Feng et al., 2002) as well as activation of Src kinase
(Alvarez et al., 2008) have been reported; other studies have also
implicated a constitutive association between AT2 receptor and
SHP-1 in overexpressing models (Feng et al., 2002; Miura et al.,
2005). Another phosphatase associated with AT2 receptor activa-
tion is MKP-1, which is a key regulator of p42/p44mapk activity.
AT2 receptor-activated MKP-1 has been observed in various cell
types, including PC12W cells (Yamada et al., 1996), ﬁbroblasts
(Horiuchi et al., 1997; Calo et al., 2010), and cardiac myocytes
(Fischer et al., 1998; Hiroi et al., 2001). Activation of MKP-1 by
AT2 leads to a decrease in p42/p44mapk activity, and is associ-
ated to growth inhibition induced by the AT2 receptor. Moreover,
Horiuchi et al. (1997) demonstrated that AT2 receptor-induced
MKP-1 activation is implicated in apoptotic effects of the AT2
receptor, leading to Bcl-2 dephosphorylation and an increase in
Bax, resulting in cell death. Finally, the serine–threonine phos-
phatase PP2A is also activated by the AT2 receptor following
Ang II binding and may be associated with AT2 receptor regu-
lation of p42/p44mapk. Indeed, in primary neuronal cultures, AT2
receptor-induced activation of PP2A is associated with inhibition
of AT1 receptor-induced p42/p44mapkphosphorylation (Huang
et al., 1995, 1996a,b) and is implicated in AT2-induced modula-
tion of potassium currents (Huang et al., 1995, 1996a; Caballero
et al., 2004). More recently, we have also shown an implication
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of PP2A activation in actin depolymerization and an increase in
neuronal migration (Kilian et al., 2008; Figure 1).
Mitogen-activated protein kinase p42/p44
Among all signaling pathways associated with AT2 receptor acti-
vation, regulation of p42/p44mapk is probably the one where
variability is the most important. The effect of AT2 receptor
stimulation on activation or inhibition of p42/p44mapk activity
is dependent on the models studied, on whether they express
AT1 receptors or not and whether cells are under physiologi-
cal or pathological conditions. Thus, AT2 receptor effects on
p42/p44mapk remain controversial. Many studies have shown that
the AT2 receptor leads to dephosphorylation of p42/p44mapk via
one the phosphatases associated with AT2 receptor signaling (see
above). This decrease in p42/p44mapk activity is associated with
inhibition of growth and pro-apoptotic effects of the AT2 recep-
tor (review in Nouet et al., 2004; Porrello et al., 2009). In addition
to activation of phosphatase, AT2 receptor-induced inhibition of
p42/p44mapk can bemediated by inhibition of growth factor recep-
tors. Indeed, in vascular smooth muscle cells overexpressing the
AT2 receptor, stimulation with Ang II decreases EGF receptor
phosphorylation and inhibits p42/p44mapk activation (Shibasaki
et al., 2001). Similar observations have also been reported in CHO
cells overexpressing the AT2 receptor (Elbaz et al., 2000). Worthy
of note is the fact that inhibition of p42/p44mapk induced by the
AT2 receptor is observed only in certain conditions, such as in cells
overexpressing the AT2 receptor or already exhibiting pathological
conditions such as serum-starving (Bedecs et al., 1997; Horiuchi
et al., 1997; Elbaz et al., 2000; Cui et al., 2001; Shibasaki et al., 2001).
By contrast, in neuronal cells such as NG108-15 and PC12W
cells, theAT2 receptor leads to sustained activationof p42/p44mapk.
In these cells, activation of p42/p44mapk is essential to AT2
receptor-induced neurite elongation (Gendron et al., 1999; Stroth
et al., 2000). In NG108-15 cells, we observed that this increase in
p42/p44mapk activity was associated with the Rap1/B-Raf pathway.
However, this Rap1 activation appears to be dependent of nerve
growth factor receptor TrkA activation (see latter; Plouffe et al.,
2006) rather than through cAMP and protein kinase A (PKA),
as usually observed with other GPCR (Figure 1). This activation
of p42/p44mapk by the AT2 receptor has also been observed in
non-neuronal COS-7 and NIH3T3 cells overexpressing the AT2
receptor (Hansen et al., 2000; De Paolis et al., 2002).
Src family kinase
There are few studies showing an implication of Src family mem-
bers in AT2 receptor signaling. However, Src family kinases (SFKs)
are key regulators in cell growth and differentiation and are impli-
cated in most growth factor signaling pathways. In the CNS, ﬁve
members of SFK are expressed, namely Src, Fyn, Lyn, Lck, and
Yes, where they act as modulators of neurotransmitter receptors as
well as in the regulation of excitatory transmission (review in Kalia
et al., 2004; Theus et al., 2006; Ohnishi et al., 2011). Recently, we
have shown that stimulation of theAT2 receptor in NG108-15 cells
leads to rapid but transient activationof SFKand that expressionof
inactive Fyn abolishedAT2 receptor-induced neurite outgrowth in
these cells (Guimond et al., 2010). However, inhibition of Fyn had
no effect on other signaling pathways induced by the AT2 receptor,
including p42/p44mapk and Rap1 activation, suggesting that itmay
be involved either downstream of these proteins, or in a parallel
pathway. Of note, among the ﬁve SFKs expressed in the brain,
only a deﬁciency in Fyn-induced neurological deﬁcits, including
impairment in spatial learning and in hippocampal development
(Grant et al., 1992; Kojima et al., 1997). Interestingly, similar phys-
iological perturbations were also observed in mice lacking the AT2
receptor (Hein et al., 1995; Ichiki et al., 1995; Okuyama et al., 1999;
Maul et al., 2008). Therefore, regulation of Fyn activity could be
considered as a new player implicated in the protective effect of
this receptor in cognitive disorders. Indeed, Fyn has been shown to
be involved in tau phosphorylation, thus regulating its afﬁnity for
tubulin and stability of microtubules, two parameters implicated
in the development of Alzheimer’s disease (AD) and other neu-
rodegenerative diseases (Lee et al., 1998, 2004). Thus, it appears
that Fyn is involved in the ﬁnal steps of induction of elongation,
but not in the initial events of AT2 receptor activation. This impli-
cation of Fyn in AT2 receptor signaling is further strengthened by
the fact that activation of SFKs, as the AT2 receptor, was shown to
be important for the induction of long-term potentiation, a key
element in learning and memory, in CA1 pyramidal neurons of
hippocampal slices (Yu et al., 1997).
To the best of our knowledge, only one other group has demon-
strated the implication of a Src family member in AT2 receptor
signaling (Alvarez et al., 2008). In this latter study, it was shown
that activation of c-Src was present in an immunocomplex includ-
ing the tyrosine phosphatase SHP-1 and theAT2 receptor following
Ang II stimulation in rat fetal membranes. Pre-incubation of
membranes with the non-selective inhibitor PP2 inhibited SHP-1
activation and c-Src association. These results indicate that c-Src
may represent an important step leading to AT2 receptor-induced
SHP-1 activation. More recently, the same group demonstrated
that this association also occurred in hindbrain membranes from
post-natal day 15 rats, and was associated with focal adhesion
kinase (p85FAK) (Seguin et al., 2012). These observations strongly
suggest that c-Src may also be implicated in cytoskeleton remod-
eling associated with neurite elongation and neuronal migration
induced by the AT2 receptor.
LINKING THE AT2 RECEPTOR WITH THE GROWTH FACTOR RECEPTORS
Recently, we demonstrated that activation of Rap1/B-Raf/
p42/p44mapk pathway by the AT2 receptor was dependent on
the nerve growth factor receptor TrkA, although the mechanism
involved remains unknown (Plouffe et al., 2006). In addition, we
further showed that a SFK member was essential for the initial
activation of TrkA by the AT2 receptor, since pre-incubation of
NG108-15 cells with the non-selective inhibitor PP1 disrupted
this effect (Guimond et al., 2010). However, although Fyn was
essential for neurite outgrowth induced by the AT2 receptor, it
did not appear to be implicated in TrkA activation, since expres-
sion of a dominant negative form did not impede AT2-induced
TrkA activation (Guimond et al., 2010). In light of recent data
obtained by Ciuffo’s group regarding the involvement of c-Src
and other SFK members with AT2 receptors (Alvarez et al., 2008;
Seguin et al., 2012), it would be of interest to see whether the asso-
ciation of the AT2 receptor with SHP-1 and c-Src is implicated
in this transactivation, and whether TrkA could be involved in
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FAK activation. Interestingly, transactivation of the TrkA recep-
tor in neurons has also been observed for the pituitary adenylyl
cyclase-activating polypeptide receptor (PACAP; Rajagopal et al.,
2004), which is also associated with neuronal development in the
cerebellum (Basille et al., 2006).
Curiously, although the expression of inactive Fyn is known
to disrupt AT2 receptor-induced neurite elongation, non-selective
inhibition of SFK in NG108-15 cells with the inhibitor PP1 is
sufﬁcient to increase neurite elongation to levels similar to those
observed with AT2 receptor stimulation (Guimond et al., 2010),
which could be a consequence of a decrease in proliferative signal.
Indeed, our group showed that induction of neurite outgrowth
was associated with a decrease in cell proliferation through inhi-
bition of PKCα and p21Ras (Gendron et al., 1999; Beaudry et al.,
2006). Moreover, as in the case of SFK, inhibition of the platelet-
derived growth factor (PDGF) receptor was sufﬁcient to induce
neurite outgrowth and to increase microtubule polymerization
more extensively than Ang II alone (Plouffe et al., 2006). These
ﬁndings are in agreement with a previous report demonstrat-
ing that expression of an inactive form of the PDGF receptor in
PC12 cells was sufﬁcient to increase neurite elongation (Vetter and
Bishop, 1995). However, whether AT2 receptor directly inhibits
PDGF receptor or inhibits its signaling pathway is still unknown.
NITRIC OXIDE AND cGMP PRODUCTION – A ROLE FOR BRADYKININ
Nitric oxide has been shown to regulate several types of K+ chan-
nels, including ATP-dependent K+ channels and Ca2+-activated
K+ channels (review in Prast and Philippu, 2001). Indeed, in
neuronal cell lines, observations with the selective AT2 receptor
agonist C21/M024 revealed that this production of NO induced
byAT2 was necessary for AT2-induced hyperpolarization of potas-
sium channel function (Gao and Zucker, 2011). Production of NO
following AT2 receptor stimulation has been observed in various
cell types, such as neuronal cells (Chaki and Inagami, 1993; Coté
et al., 1998; Gendron et al., 2002; Zhao et al., 2003; Muller et al.,
2010), vascular endothelial cells (Wiemer et al., 1993; Seyedi et al.,
1995; Saito et al., 1996; Thorup et al., 1998; Baranov andArmstead,
2005) as well as in smooth muscle cells (de Godoy et al., 2004). It is
already well accepted that AT2 receptor activation plays an impor-
tant role in the control of renal function particularly in chronic
kidney diseases. The AT2 receptor is believed to counterbalance
the effects of the AT1 receptor at least by inﬂuencing vasodilation
through NO production and natriuresis (Carey and Padia, 2008;
Siragy, 2010; Siragy and Carey, 2010). This promoter effect of
AT2 on natriuresis in pathological conditions (obese Zucker rats)
was also recently conﬁrmed using C21/M024 (Ali and Hussain,
2012). Activation of NOS by the AT2 receptor can occur by direct
signaling such as in neuronal cells, or indirectly via stimulation
of bradykinin production and subsequent activation of its recep-
tor B2. Indeed, heterodimerization between the AT2 receptor and
bradykinin has also been described in PC12W cells (Abadir et al.,
2006). Moreover, it is already known that bradykinin canmodulate
AT2 receptor-induced NO production (Siragy and Carey, 1996;
Gohlke et al., 1998; Searles and Harrison, 1999). Such involve-
ment of B2 receptors in AT2 receptor-induced production of NO
is of prime importance in the modulation of cerebral blood ﬂow.
Indeed, an AT2-induced increase in spatial learning was recently
observed to be associated with an increase in cerebral blood ﬂow,
an effect reduced by co-administration of the B2 receptor antago-
nist icatibant. This observation strongly suggests that the beneﬁcial
effect of the AT2 receptor in cognitive function is partly dependent
on bradykinin (Jing et al., 2012). In addition, Abadir et al. (2003)
demonstrated in conscious bradykininB2-null andwild-typemice
that the AT2 receptor can induce production of NO in both null
and wild-type models, indicating that the B2 receptor may partic-
ipate in this process, although is not the only means for the AT2
receptor to induce NO production.
AT2 RECEPTOR ASSOCIATED PROTEINS
ATIP
Recently, using a yeast two-hybrid system, theATIPwas cloned and
identiﬁed as a protein interacting with the C-terminal tail of the
AT2 receptor (Nouet et al., 2004). This protein is expressed as ﬁve
different transcripts, namely ATIP1, ATIP2, ATIP3a, ATIP3b, and
ATIP4 (review in Rodrigues-Ferreira and Nahmias, 2010; Hori-
uchi et al., 2012). While ATIP3 appears to be the major transcript
in tissues, ATIP1 and ATIP4 are mainly expressed in the brain,
indicating that they may play biological roles in brain functions.
ATIP2, on the other hand, is almost undetectable by real-time
PCR (Di Benedetto et al., 2006). In CHO cells expressing the
AT2 receptor, ATIP is known to decrease growth factor-induced
p42/p44mapk activation and DNA synthesis, therefore decreasing
cell proliferation, as well as decrease insulin receptor autophos-
phorylation, similarly to the AT2 receptor. Of particular interest is
the fact that, although expression of the AT2 receptor was essen-
tial in this instance, stimulation by Ang II was not necessary,
and that ATIP was able to exert its effect by its sole expression.
Implication of ATIP in AT2 receptor-induced neurite outgrowth
has also been reported. In this context, Ang II stimulation of the
AT2 receptor induces translocation of ATIP with SHP-1 into the
nucleus, resulting in the transactivation of MMS2 (Li et al., 2007).
Moreover, ATIP, also known as ATBP50 (AT2 receptor binding
protein of 50 kDa), has been reported as a membrane-associated
Golgi protein implicated in intracellular localization of the AT2
receptor and necessary for its membrane expression (Wruck et al.,
2005). ATIP3, which is also expressed in the CNS, has been shown
to strongly interact with stabilized microtubules in a model of
breast cancer, suggesting an implication on cell division, where it
induces a delayed metaphase, thus decreasing tumor progression
(Rodrigues-Ferreira et al.,2009). Thebrain-speciﬁc isoformATIP4
is highly expressed in the cerebellum and fetal brain, two sites
where the AT2 receptor is also highly expressed. Therefore consid-
ering (i) the previously described function of the AT2 receptor in
preservation of cognitive function, (ii) the role of ATIP protein in
AT2 receptor function, and (iii) the link betweenATIP protein and
microtubule cytoskeleton, it could be suggested that regulation
of ATIP expression and regulation of its association with the AT2
receptor could be an important element to consider with regard
to the development of neurological disorders, such as AD.
PLZF
Association between the AT2 receptor and the promyelocytic
leukemia zinc ﬁnger (PLZF) protein has been observed using
a yeast two-hybrid system (Senbonmatsu et al., 2003). In CHO
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cells expressing both PLZF and AT2 receptors, Ang II stimulation
induces co-localization of PLZF with theAT2 receptor, followed by
internalization of the complex. This observation is in contrast with
other studies observing no internalization of the AT2 receptor fol-
lowingAng II stimulation (Hunyady et al., 1994; Hein et al., 1997).
Since internalization of the receptor was observed only in cells
expressing PLZF, this could represent a new regulatory pathway of
AT2 receptor function, speciﬁc only to selected cell types. However,
beside internalization of AT2 receptor, a recent study showed that
PLZF was implicated in neuroprotection in a stroke model (Seidel
et al., 2011). In this study, the authors showed that PLZF exerts
neuroprotective effect in a model of in vitro glutamate toxicity.
They also showed that overexpression of PLZF in neuronal cells in
culture induced a signiﬁcant increase in AT2 receptor expression,
suggesting that PLZF could also be implicated in the regulation of
AT2 receptor expression.
PPARγ
A new partner for the AT2 receptor has recently emerged from
the study of Zhao et al. (2005) who observed that neurite out-
growth induced by AT2 receptor stimulation in PC12W cells was
dependent on the activation of peroxisome proliferator-activated
receptor gamma (PPARγ). This observation is in keeping with the
implication of PPARγ in NGF-induced neurite outgrowth in the
same cell type (Fuenzalida et al., 2005), clearly suggesting a pos-
sible crosstalk between the AT2 receptor and NGF pathways. This
hypothesis is further reinforced by the observation that inhibition
of the NGF receptor TrkA signiﬁcantly decreases AT2 receptor-
induced neurite outgrowth (Plouffe et al., 2006). Moreover, Iwai
et al. (2009), using atherosclerotic ApoE-KO mice with an AT2
receptor deﬁciency (AT2R/ApoEdouble knockoutmice), observed
that the lack of AT2 receptor expression decreased the expression
of PPARγ in adipocytes cells. These observations strongly suggest
a link between the AT2 receptor and PPARγ functions. PPARγ is a
transcriptional factor regulating the expression of multiple genes,
hence promoting the differentiation and development of various
tissues, speciﬁcally in adipose tissue, brain, placenta, and skin.
Interestingly, neuroprotective effects of PPARγ agonist have also
been observed (review in Gillespie et al., 2011). However, a major
component of the hypothesis regarding the possible implication of
PPARγ in AT2 receptor function is the PPARγ-like activity asso-
ciated with certain ARBs, including telmisartan, irbesartan, and
candesartan (Benson et al., 2004; Schupp et al., 2004; review in
Horiuchi et al., 2012). Indeed, there is some evidence suggesting
that this PPARγ activation following blockade of the AT1 receptor
could be part of its anti-inﬂammatory and anti-oxidative effects,
leading to neuroprotection against ischemia and amyloid β (Aβ)
accumulation (Tsukuda et al., 2009; Iwanami et al., 2010; Washida
et al.,2010). PPARγhas alsobeen implicated inneural cell differen-
tiation and death, as well as inﬂammatory and neurodegenerative
conditions (review in Gillespie et al., 2011).
LESSONS FROM NEURONAL DIFFERENTIATION: HOW CAN
THE AT2 RECEPTOR IMPROVE BRAIN FUNCTION?
ROLE OF THE AT2 RECEPTOR IN NEURONAL REGENERATION
The capacity for nerve regeneration in lower vertebrates has been
mostly lost in higher vertebrates and regeneration within the
CNS in mammals is essentially inexistent. However, after injury
in the peripheral nervous system, regeneration can be achieved
successfully. Observations that AT2 receptor stimulation induces
neurite elongation associated with modulation of MAP expression
strongly suggested that this effect could also be observed following
nerve injury. In 1998, two studies demonstrated that theAT2 recep-
tor improved nerve recovery in both optic (Lucius et al., 1998)
and sciatic (Gallinat et al., 1998) nerve following nerve crush or
in perivascular nerves implicated in vasodilation (Hobara et al.,
2007). This effect was accompanied by an increase in AT2 receptor
expression, the activation of NFκB and induction of growth-
associated protein (GAP-43) leading to a reduction in lesion size.
Moreover, Reinecke et al. (2003) demonstrated that activation of
NFκB by the AT2 receptor was an essential step to recovery fol-
lowing sciatic nerve crush. This implication of AT2 receptor in
neuronal regeneration has even led to the suggestion that Ang II,
via the AT2 receptor, could act as a neurotrophic factor.
AT2 RECEPTOR IN COGNITIVE FUNCTION
There is increasing evidence suggesting that theAT2 receptor could
be associated with improvement of cognitive function following
cerebral ischemia-induced neuronal injury (Iwai et al., 2004; Li
et al., 2005; Mogi et al., 2006; McCarthy et al., 2009). Indeed, it has
been shown that central administration of CGP42112A increases
neuronal survival and minimizes experimental post-stroke injury
(McCarthy et al., 2009), indicating that activation of brain AT2
receptors exhibits a neuroprotective effect. More recently, stimu-
lation of theAT2 receptor with the selective agonist C21/M024 was
observed to prevent cognitive decline in an AD mouse model with
intracerebroventricular injection of Aβ(1-40) (Jing et al., 2012).
Indeed, some of the signaling pathways described above may be
linked to improvement in impaired signaling functions as observed
inAD. One of the major hallmarks of AD isAβ deposition in senile
plaques and the presence of neuroﬁbrillary tangles (NFTs). For-
mation of NFTs is a consequence of protein tau accumulation,
due to its hyperphosphorylation, and the dissociation of micro-
tubules. Thus, regulation of tau phosphorylation is of paramount
importance with regard to AD progression. On the other hand,
several studies have reported that the AT2 receptor activates PP2A
phosphatase (Huang et al., 1995, 1996a; Kilian et al., 2008), which
is markedly deﬁcient in AD (Gong et al., 1993, 2000; Wang et al.,
2007) and implicated in glycogen synthase kinase-3 (GSK-3) inac-
tivation via a sustained increase in p42/p44mapk. Since tau is
a substrate for PP2A phosphatase, GSK-3 and Fyn, the latter
of which is also implicated in the AT2 receptor effect on neu-
rite outgrowth (Guimond et al., 2010), AT2 receptor activation
could participate in controlling the equilibriumbetween tau phos-
phorylation and dephosphorylation (Hernandez and Avila, 2008;
Hanger et al., 2009; Hernandez et al., 2009). In addition to act-
ing on tau regulation, the AT2 receptor may also improve neurite
architecture, through effects onMAPs, as observed in neuronal cell
lines (Laﬂamme et al., 1996; Meffert et al., 1996; Coté et al., 1999;
Li et al., 2007). The observation that central AT2 receptor acti-
vation using its selective agonist C21/M024 decreases cognitive
loss induced by Aβ intracerebroventricular injection lends fur-
ther support to this hypothesis (Jing et al., 2012). Although the
mechanisms underlying these neuroprotective effects of the AT2
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receptor remain to be fully elucidated, they may include PPARγ
and the protein MMS2 (Mogi et al., 2006, 2008; for recent reviews
see Gallo-Payet et al., 2011, 2012).
Moreover, as indicated earlier, another important feature of
AT2 receptor signaling is induction of NO and cGMP produc-
tion. Recently, Jing et al. (2012) observed that direct stimulation
of central AT2 receptors increases NO via a bradykinin-dependent
pathway, an effect which leads to an increase in cerebral blood
ﬂow and enhanced spatial memory. A further study also showed
that administration of C21/M024 reduced early renal inﬂam-
matory response with production of NO and cGMP (Matavelli
et al., 2011). This increase in NO-cGMP production has also been
shown to lead to a decrease in nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH) superoxide production (Volpe et al.,
2003;Widdop et al., 2003; de la Torre, 2004; Steckelings et al., 2005;
Iadecola et al., 2009), thus reducing oxidative stress and poten-
tially associated neuronal apoptosis. This hypothesis is coherent
with the observation that the AT2 receptor attenuates chemical
hypoxia-induced caspase-3 activation inprimary cortical neuronal
cultures (Grammatopoulos et al., 2004b). Finally, inﬂammation
is also a common feature of neurodegenerative diseases. In
this regard, a recent study conducted in primary cultures of
human and murine dermal ﬁbroblasts, has shown that C21/M024
has anti-inﬂammatory effects, inhibiting tumor necrosis factor
(TNF)-α-induced interleukin-6 levels and NFκB activity. This
effect was notably initiated through increased activation of protein
phosphatases and increased synthesis of epoxyeicosatrienoic acid
(Rompe et al., 2010).
CONCLUSION
Since its identiﬁcation in the early 90s, the AT2 receptor has
been and still is shrouded by controversy, its low expression in
the adult and its atypical signaling pathways adding to the chal-
lenge of studying this receptor. Thanks to the major advances
achieved in the past few years, several studies have conﬁrmed
that stimulation of the AT2 receptor activates multiple signal-
ing pathways which are linked to beneﬁcial effects on neuronal
functions (including excitability, differentiation, and regenera-
tion), inﬂammation, oxidative stress, and cerebral blood ﬂow
(Figure 1). Several neurodegenerative diseases (including cog-
nitive deﬁcits and dementia) are closely associated with these
neuronal and synaptic dysfunctions (Iadecola, 2004; Zlokovic,
2005; LaFerla et al., 2007; Boissonneault et al., 2009; Mucke, 2009;
Nelson et al., 2009). Moreover, an increasing number of stud-
ies suggest that the protective effects of ARBs on brain damage
and cognition may result not only from the inhibition of AT1
receptor effects, but also from the beneﬁcial effect due to unop-
posed activation of the AT2 receptor. Thus, if further research
conﬁrms the promising early results obtained with the recently
developed selective non-peptide AT2 receptor agonist C21/M024,
the latter may represent a new pharmacological tool in the ﬁght
against neurological cognitive disorders. In addition, unraveling
the underlying effects of the AT2 receptor on neuronal plasticity
may lead to the development of even more potent and selective
therapies.
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